Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | KLK1 | P06870 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3876352 | 0.85 | F10 (0.55) | F10F2KLK1 | |
| SCHEMBL220661 | 0.82 | F10 (0.89) | F10MAPK1 | |
| SCHEMBL219798 | 0.82 | F10 (1.00) | F10SMN1; SMN2MAPK1 | |
| SCHEMBL221783 | 0.81 | F10 (0.71) | F10SMN1; SMN2KMT2ALMNAMAPK1 | |
| SCHEMBL223513 | 0.80 | F10 (0.68) | F10SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL219591 | 0.78 | F10 (0.72) | F10SMN1; SMN2KMT2ALMNAMAPK1 | |
| Fumaric Acid SCHEMBL221972 | 0.77 | F10 (0.89) | F10SMN1; SMN2MAPK1 | |
| SCHEMBL222580 | 0.76 | F10 (0.66) | F10LMNAF2 | |
| SCHEMBL222308 | 0.76 | F10 (0.65) | F10SMN1; SMN2LMNAMAPK1 | |
| SCHEMBL221322 | 0.74 | F10 (0.66) | F10LMNAMAPK1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | claimed |
| US-8088925-B2 | low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents | SANOFI-AVENTIS (FR) | 2012-01-03 | — | — | US | disclosed |